Form 4: Cogent Biosciences Chief Scientific Officer Awarded Stock Options

Cogent Biosciences' Chief Scientific Officer, John Edward Robinson, was granted 270,000 stock options on January 23, 2025.

Summary

• John Edward Robinson, the Chief Scientific Officer of Cogent Biosciences, was granted 270,000 stock options.
• The options have an exercise price of $8.89.
• The options vest in equal monthly installments over a four-year period.
• The options expire on January 23, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. The sentiment is neutral to positive.

Positives

• The grant of stock options aligns the Chief Scientific Officer's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Risks

• The value of the options is dependent on the future performance of Cogent Biosciences' stock price.
• There is a risk that the options may not be valuable if the stock price does not increase above the exercise price.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to incentivize performance and align management interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard practice for compensating executives in the biotech industry.
• The vesting schedule of four years is typical for such grants, encouraging long-term commitment.
• The exercise price of $8.89 is a key factor in determining the value of the options, and will be compared to the market price of the stock over time.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the Chief Scientific Officer to increase the company's value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, executive compensation, insider trading, Cogent Biosciences, COGT, John Edward Robinson, Chief Scientific Officer